IL1B and COVID-19: The latter leads to abundant IL-1β release and uncontrolled systemic hyperinflammation, resulting in pulmonary damage, as well as subsequent epitheliopathy and coagulopathy, reflecting widespread organ damage as this occurs in severe COVID-19 [27].